KP Management LLC Decreases Stock Holdings in Danaher Co. (NYSE:DHR)

KP Management LLC reduced its position in shares of Danaher Co. (NYSE:DHR) by 14.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,500 shares of the conglomerate’s stock after selling 3,000 shares during the period. Danaher accounts for about 1.6% of KP Management LLC’s portfolio, making the stock its 26th largest holding. KP Management LLC’s holdings in Danaher were worth $4,622,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Tsfg LLC raised its holdings in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new stake in Danaher in the second quarter valued at $25,000. nVerses Capital LLC acquired a new position in shares of Danaher in the 2nd quarter worth approximately $25,000. Redmont Wealth Advisors LLC acquired a new position in Danaher during the 1st quarter worth about $30,000. Finally, Richardson Financial Services Inc. purchased a new position in Danaher in the 4th quarter valued at approximately $42,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The disclosure for this sale can be found here. In the last three months, insiders sold 39,659 shares of company stock valued at $11,042,433. Company insiders own 11.10% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $274.54 on Wednesday. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The stock has a market cap of $203.35 billion, a P/E ratio of 46.53, a PEG ratio of 4.55 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The firm has a 50-day moving average of $270.98 and a two-hundred day moving average of $258.24.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s quarterly revenue was down 2.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.05 earnings per share. On average, research analysts expect that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is presently 18.31%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on DHR shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Danaher in a research report on Friday, September 6th. Bank of America increased their target price on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Stifel Nicolaus upped their target price on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Stephens assumed coverage on Danaher in a report on Tuesday. They set an “overweight” rating and a $315.00 price objective on the stock. Finally, StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Seven investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $282.12.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.